Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
Open Access
- 31 August 2026
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Abstract
Background: Neoadjuvant therapy (NAT) has shifted rectal cancer management toward organ preservation. However, achieving a complete response (CR) for “watch-and-wait” strategies is hindered by high response heterogeneity. Although immunotherapy-combined NAT has expanded the candidate pools, the predictive significance of molecular alterations remains unclear. Objectives: This study aimed to evaluate clinical and genomic profiles of rectal cancer patients undergoing NAT to identify response predictors and to develop a nomogram for estimating CR probability. Design: Retrospective, single-center cohort study. Methods: This study included 437 patients with rectal adenocarcinoma at Fudan University Shanghai Cancer Center between December 2019 and March 2023. Patients underwent paired tumor and germline genomic sequencing (887-gene panel) before NAT. Logistic and Cox regression analyses were performed to identify clinical and genetic risk factors associated with tumor response and long-term survival. Results: Of the 437 patients, 96.6% had microsatellite-stable (MSS) tumors. In the MSS locally advanced rectal cancer cohort (N = 307), the CR rate was 35.5%. Multivariate analysis identified immunotherapy-combined NAT (iTNT) (OR 4.41, 95% CI: 2.42–8.27), SYNE1 mutation (OR 2.12, 95% CI: 1.06–4.26), negative mesorectal fascia (MRF) status (OR 0.34, 95% CI: 0.17–0.66), and lower tumor location (OR 0.48, 95% CI: 0.27–0.84) as independent predictors of CR. KRAS mutation was the sole independent predictor of reduced disease-free survival (DFS; HR 1.93, 95% CI: (1.11–3.36), p = 0.020). KRAS G12D subtype was associated with the worst 2-year distant metastasis-free survival (71.3%) and exhibited a distinct predilection for lung metastasis. The clinical-genomic nomogram yielded strong discrimination (AUC = 0.705) and calibration, with favorable DCA net benefit. Conclusion: Clinical and genomic features jointly determine outcomes in MSS rectal cancer. SYNE1 mutation serves as a novel biomarker for CR, while KRAS mutations, especially the G12D subtype, identify patients at high risk for systemic relapse. The clinical-genomic nomogram facilitates individualized selection for organ-preservation strategies.Keywords
Funding Information
- Wu Jieping Medical Foundation (HYXH2021010)
- National Key Research and Development Program of China Stem Cell and Translational Research (2022YFC2503700)
- National Key Research and Development Program of China Stem Cell and Translational Research (2022YFC2503702)
- National Natural Science Foundation of China (82272732)
- National Natural Science Foundation of China (82473237)
This publication has 31 references indexed in Scilit:
- Predictive value of rectal MRI variables for pathological complete response in locally advanced rectal cancer following neoadjuvant chemoradiotherapyInternational Journal of Colorectal Disease, 2025
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trialAnnals of Oncology, 2024
- Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 studySignal Transduction and Targeted Therapy, 2024
- Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancerInternational Journal of Cancer, 2024
- International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancerNature Reviews Clinical Oncology, 2021
- Use of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2021
- Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsInternational Journal of Cancer, 2019
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry studyThe Lancet, 2018
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerCancer Cell, 2018
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012